Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00851045 · ClinicalTrials.gov registry record · Phase 2
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00851045 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 17 participants.
The verdict
NCT00851045, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with irinotecan, 5-FU and leucovorin in the second-line treatment of subject with metastatic colorectal cancer
Interventions
- DRUG Irinotecan
- DRUG Leucovorin calcium
- DRUG 5-Fluorouracil (bolus)
- DRUG 5-Fluorouracil (infusional)
- DRUG CT-322
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00851045
The ClinicalTrials.gov registry entry for NCT00851045 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Irinotecan is the first listed.
NCT00851045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00851045 about?
NCT00851045 is a clinical study titled "Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer". The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with irinotecan, 5-FU and leucovorin in the second-line treatment of subject with metastatic colorectal cancer
What is the current status of trial NCT00851045?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2009-10. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00851045?
The interventions under investigation include: Irinotecan (DRUG), Leucovorin calcium (DRUG), 5-Fluorouracil (bolus) (DRUG), 5-Fluorouracil (infusional) (DRUG), CT-322 (DRUG).
Who is sponsoring clinical trial NCT00851045?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.